Rachna T Shroff, MD, MS, FASCO
Rachna T. Shroff, MD, MS, FASCO, is associate director of clinical investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Comprehensive Cancer Center. She also is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology for the University of Arizona College of Medicine – Tucson, and Medical Director for the Oncology Service Line with Banner Health. She came to the U of A Cancer Center from MD Anderson Cancer Center in Houston, where she was on faculty from 2010-18 after completing her medical oncology fellowship there.
Cancer Focus
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary Subcommittee co-chair for the Southwest Oncology Group (SWOG) and as Chair for GI ASCO 2024, a meeting sponsored by the American Society of Clinical Oncology focused on gastrointestinal cancers. She was elected to serve on the ASCO Nominating Committee from 2022-2024 and currently is an Associate Editor for the ASCO Daily News and serves on the ASCO Communications Committee. Dr. Shroff was award the Fellow of ASCO (FASCO) designation for her service to this professional society in 2023. She has also been a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation.
Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and was the national PI for SWOG 1815 which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. It was the first randomized phase 3 trial in the US for biliary cancers and was one of the fastest accruing trials in SWOG. The study was published in the Journal of Clinical Oncology in 2024.
Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area including many that have led to FDA approvals for these diseases. She also holds NCI peer-reviewed funding focused on supporting the Cancer Center’s efforts to expand clinical research across the state of Arizona.